Now Trending: Updated Colonoscopy Guidelines, Out-of-Pocket Caps for Cancer Patients
Drug Topics
SEPTEMBER 14, 2024
Check out this recap of articles published on our sister sites during the past week.
Sat.Sep 14, 2024
247 
STAT+: Pfizer drug shows promise in cancer-related condition that causes weight loss and weakness
STAT
SEPTEMBER 14, 2024
BARCELONA, Spain — Patients with advanced cancers often develop a secondary condition that causes them to shed weight, making it even harder to tolerate their cancer treatments. Called cachexia, it’s an under-recognized syndrome that researchers are still trying to tease out, and one that’s attracting more interest from drugmakers.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Small Doses: September 9 to September 13
Drug Topics
SEPTEMBER 14, 2024
Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.
STAT+: Incyte’s checkpoint inhibitor staves off disease progression in anal cancer trial
STAT
SEPTEMBER 14, 2024
BARCELONA, Spain — A widely used immunotherapy approach helped stave off disease progression in patients with a type of anal tumor, researchers reported Saturday, potentially setting up the drug for approval in a cancer that’s largely caused by human papillomavirus. The Phase 3 trial tested the PD-1 targeting antibody retifanlimab in combination with chemotherapy versus chemotherapy alone in patients with recurrent or metastatic squamous cell carcinoma of the anal canal.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
ESMO 2024 – Today’s oncological roots are branching
pharmaphorum
SEPTEMBER 14, 2024
ESMO 2024 began on Friday 13th September. Prof Andres Cervantes discussed how building trust has been a several generation development, following five decades of effort in the oncological space.
Emerging Frontiers: The Gut Microbiome's Role in Enhancing Cancer Immunotherapy and Treatment Outcomes
Pharmacy Times
SEPTEMBER 14, 2024
An ESMO 2024 presentation explores the growing role of the gut microbiome in immunotherapy response, emerging diagnostic tools such as PCR chips, and innovative therapies such as fecal microbiota transplantation and microbiome-preserving strategies to improve patient outcomes.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
Experts Highlight the Need for Greater Diversity in Dermatological Clinical Research
Pharmacy Times
SEPTEMBER 14, 2024
Not only do diverse clinical cohorts improve the strength of the data, but it improves public trust in clinicians and the medical system as a whole.
ESMO: With survival win, Merck's Keytruda redeems itself in early triple-negative breast cancer
Fierce Pharma
SEPTEMBER 14, 2024
In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative breast cancer (TNBC). | In 2021, the FDA blasted Merck for using premature data to pursue a Keytruda approval in early-stage triple-negative breast cancer. Now, the PD-1 inhibitor has gold-standard overall survival data to back its case.
Unveiling the Microbiota's Role in Cancer: From Tumorigenesis to Treatment
Pharmacy Times
SEPTEMBER 14, 2024
The gut and intratumoral microbiota influence cancer development, progression, and treatment responses, highlighting the potential for treatment strategies that leverage these microbial interactions to enhance cancer therapies.
Let's personalize your content